within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01E_ProteinKinaseInhibitors.L01EX27_Capivasertib;

model Capivasertib
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C_enteral(
    weight = 70,
    F = 0.73,
    Cl = 1.5638888888888888e-05,
    adminDuration = 600,
    adminMass = 400 / 1000000,
    adminCount = 1,
    Vd = 0.094,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.010333333333333333,
    Tlag = 15.0,
    Vdp = 0.074,
    k12 = 2.4999999999999998e-05,
    k21 = 2.4999999999999998e-05);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Capivasertib</td></tr><tr><td>ATC code:</td><td>L01EX27</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>400</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>94</td><td>L</td></tr>
    <tr><td>clearance:</td><td>56.3</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Capivasertib is an oral, selective pan-AKT kinase inhibitor developed for the treatment of various cancers, including breast cancer. It is currently approved in combination with fulvestrant for the treatment of hormone receptor-positive, HER2-negative advanced or metastatic breast cancer in adults who have received prior endocrine therapy.</p><h4>Pharmacokinetics</h4><p>Population pharmacokinetics in adult cancer patients after oral administration; values based on phase I/II clinical trials.</p><h4>References</h4><ol><li><p>Fernandez-Teruel, C, et al., &amp; Zhou, D (2024). Population Pharmacokinetics of Capivasertib in Patients with Advanced or Metastatic Solid Tumours. <i>Clinical pharmacokinetics</i> 63(8) 1191–1204. DOI:<a href=\"https://doi.org/10.1007/s40262-024-01407-x\">10.1007/s40262-024-01407-x</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/39127854/\">https://pubmed.ncbi.nlm.nih.gov/39127854</a></p></li><li><p>Miller, C, et al., &amp; Cullberg, M (2024). Pharmacokinetic study of capivasertib and the CYP3A4 substrate midazolam in patients with advanced solid tumors. <i>Cancer chemotherapy and pharmacology</i> 94(2) 223–235. DOI:<a href=\"https://doi.org/10.1007/s00280-024-04667-3\">10.1007/s00280-024-04667-3</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/38643311/\">https://pubmed.ncbi.nlm.nih.gov/38643311</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.L.L01EX27 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Capivasertib;
